17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Association Between e-Cigarette Use and Depression in the Behavioral Risk Factor Surveillance System, 2016-2017

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          Question

          What is the association between electronic cigarette (e-cigarette) use and depression?

          Findings

          In this cross-sectional study of 892 394 participants in the Behavioral Risk Factor Surveillance System from 2016 to 2017, e-cigarette users had higher odds of reporting a history of clinical diagnosis of depression compared with participants who never used e-cigarettes. In addition, increased frequency of e-cigarette use was associated with incrementally higher odds of reporting depression.

          Meaning

          These findings highlight the need for longitudinal studies to examine the association between e-cigarette use and depression, which may be bidirectional.

          Abstract

          This cross-sectional study examines the association between electronic cigarette (e-cigarette) use and depression in a nationally representative sample of the adult population in the United States.

          Abstract

          Importance

          The prevalence of the use of electronic cigarettes (e-cigarettes) in the United States has grown rapidly since their introduction to the market more than a decade ago. While several studies have demonstrated an association between combustible cigarette smoking and depression, the association between e-cigarette use and depression has not been thoroughly studied.

          Objective

          To examine the association between e-cigarette use and depression in a nationally representative sample of the adult population in the United States.

          Design, Setting, and Participants

          Cross-sectional study of the Behavioral Risk Factor Surveillance System database, 2016 to 2017. The Behavioral Risk Factor Surveillance System is the largest national telephone-based survey of randomly sampled adults in the United States. A total of 892 394 participants with information on e-cigarette use and depression were included. Data analysis was conducted in May 2019.

          Exposures

          Electronic cigarette use status defined by self-report as never, former, or current use.

          Main Outcomes and Measures

          Self-reported history of a clinical diagnosis of depression.

          Results

          Of the 892 394 participants (414 326 [29.0%] aged ≥60 years; 502 448 [51.3%] women), there were 28 736 (4.4%) current e-cigarette users, of whom 13 071 (62.1%) were aged between 18 and 39 years. Compared with never e-cigarette users, current e-cigarette users were more likely to be single, male, younger than 40 years, and current combustible cigarette smokers (single, 120 797 [24.3%] vs 10 517 [48.4%]; men, 318 970 [46.6%] vs 14 962 [60.1%]; aged 18-39 years, 129 085 [32.2%] vs 13 071 [62.1%]; current combustible cigarette use, 217 895 [7.9%] vs 8823 [51.8%]). In multivariable adjusted models, former e-cigarette users had 1.60-fold (95% CI, 1.54-1.67) higher odds of reporting a history of clinical diagnosis of depression than never users, whereas current e-cigarette users had 2.10 (95% CI, 1.98-2.23) times higher odds. Additionally, higher odds of reporting depression were observed with increased frequency of use among current e-cigarette users compared with never users (daily use: odds ratio, 2.39; 95% CI, 2.19-2.61; occasional use: odds ratio, 1.96; 95% CI, 1.82-2.10). Similar results were seen in subgroup analyses by sex, race/ethnicity, smoking status, and student status.

          Conclusions and Relevance

          This study found a significant cross-sectional association between e-cigarette use and depression, which highlights the need for prospective studies analyzing the longitudinal risk of depression with e-cigarette use. If confirmed by other study designs, the potential mental health consequences may have regulatory implications for novel tobacco products.

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found

          Prevalence and Distribution of E-Cigarette Use Among U.S. Adults: Behavioral Risk Factor Surveillance System, 2016

          Contemporary data on the prevalence of e-cigarette use in the United States are limited.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Metal Concentrations in e-Cigarette Liquid and Aerosol Samples: The Contribution of Metallic Coils

            Background: Electronic cigarettes (e-cigarettes) generate an aerosol by heating a solution (e-liquid) with a metallic coil. Whether metals are transferred from the coil to the aerosol is unknown. Objective: Our goal was to investigate the transfer of metals from the heating coil to the e-liquid in the e-cigarette tank and the generated aerosol. Methods: We sampled 56 e-cigarette devices from daily e-cigarette users and obtained samples from the refilling dispenser, aerosol, and remaining e-liquid in the tank. Aerosol liquid was collected via deposition of aerosol droplets in a series of conical pipette tips. Metals were reported as mass fractions ( μ g / kg ) in liquids and converted to mass concentrations ( mg / m 3 ) for aerosols. Results: Median metal concentrations ( μ g / kg ) were higher in samples from the aerosol and tank vs. the dispenser (all p < 0.001 ): 16.3 and 31.2 vs. 10.9 for Al; 8.38 and 55.4 vs. < 0.5 for Cr; 68.4 and 233 vs. 2.03 for Ni; 14.8 and 40.2 vs. 0.476 for Pb; and 515 and 426 vs. 13.1 for Zn. Mn, Fe, Cu, Sb, and Sn were detectable in most samples. Cd was detected in 0.0, 30.4, and 55.1% of the dispenser, aerosol, and tank samples respectively. Arsenic was detected in 10.7% of dispenser samples (median 26.7 μ g / kg ) and these concentrations were similar in aerosol and tank samples. Aerosol mass concentrations ( mg / m 3 ) for the detected metals spanned several orders of magnitude and exceeded current health-based limits in close to 50% or more of the samples for Cr, Mn, Ni, and Pb. Conclusions: Our findings indicate that e-cigarettes are a potential source of exposure to toxic metals (Cr, Ni, and Pb), and to metals that are toxic when inhaled (Mn and Zn). Markedly higher concentrations in the aerosol and tank samples versus the dispenser demonstrate that coil contact induced e-liquid contamination. https://doi.org/10.1289/EHP2175
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Smoking, smoking cessation, and major depression.

              A relationship between cigarette smoking and major depressive disorder was suggested in previous work involving nonrandomly selected samples. We conducted a test of this association, employing population-based data (n = 3213) collected between 1980 and 1983 in the St Louis Epidemiologic Catchment Area Survey of the National Institute of Mental Health. A history of regular smoking was observed more frequently among individuals who had experienced major depressive disorder at some time in their lives than among individuals who had never experienced major depression or among individuals with no psychiatric diagnosis. Smokers with major depression were also less successful at their attempts to quit than were either of the comparison groups. Gender differences in rates of smoking and of smoking cessation observed in the larger population were not evident among the depressed group. Furthermore, the association between cigarette smoking and major depression was not ubiquitous across all psychiatric diagnoses. Other data are cited indicating that when individuals with a history of depression stop smoking, depressive symptoms and, in some cases, serious major depression may ensue.
                Bookmark

                Author and article information

                Journal
                JAMA Netw Open
                JAMA Netw Open
                JAMA Netw Open
                JAMA Network Open
                American Medical Association
                2574-3805
                4 December 2019
                December 2019
                4 December 2019
                : 2
                : 12
                : e1916800
                Affiliations
                [1 ]The American Heart Association Tobacco Regulation and Addiction Center, Dallas, Texas
                [2 ]Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Baltimore, Maryland
                [3 ]Department of Medicine, Yale New Haven Hospital, New Haven, Connecticut
                [4 ]Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
                [5 ]Johns Hopkins University, Baltimore, Maryland
                [6 ]Department of Radiology and Neuroradiology, Charité, Berlin, Germany
                [7 ]Section on Tobacco, Alcohol, and Drug Use, Department of Population Health, School of Medicine, New York University, New York
                [8 ]Public Health Research Center, New York University, Abu Dhabi, United Arab Emirates
                [9 ]Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas
                [10 ]University of Louisville, Louisville, Kentucky
                [11 ]Boston University, Boston, Massachusetts
                Author notes
                Article Information
                Accepted for Publication: October 4, 2019.
                Published: December 4, 2019. doi:10.1001/jamanetworkopen.2019.16800
                Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2019 Obisesan OH et al. JAMA Network Open.
                Corresponding Author: Michael J. Blaha, MD, MPH, Department of Cardiology, Johns Hopkins University, Blalock 524D1 JHH, 600 N Wolfe St, Baltimore, MD 21287 ( mblaha1@ 123456jhmi.edu ).
                Author Contributions: Drs Obisesan and Osei had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
                Concept and design: Obisesan, Mirbolouk, Osei, Orimoloye, Uddin, Dzaye, El Shahawy, Bhatnagar, Stokes, Benjamin, De Filippis, Blaha.
                Acquisition, analysis, or interpretation of data: Obisesan, Mirbolouk, Osei, Orimoloye, Uddin, Dzaye, El Shahawy, Al Rifai, De Filippis, Blaha.
                Drafting of the manuscript: Obisesan, Osei, Orimoloye, Uddin, Dzaye, Al Rifai, Bhatnagar.
                Critical revision of the manuscript for important intellectual content: Obisesan, Mirbolouk, Osei, Orimoloye, Uddin, Dzaye, El Shahawy, Bhatnagar, Stokes, Benjamin, De Filippis, Blaha.
                Statistical analysis: Obisesan, Mirbolouk, Osei, Orimoloye, Uddin, Dzaye, El Shahawy, Al Rifai.
                Obtained funding: Bhatnagar, De Filippis, Blaha.
                Administrative, technical, or material support: Osei, Orimoloye, Dzaye, Stokes, Blaha.
                Supervision: Uddin, Dzaye, De Filippis, Blaha.
                Conflict of Interest Disclosures: Dr Stokes reported receiving research funding from Ethicon, a subsidiary of Johnson and Johnson. Dr Benjamin reported receiving grants from the National Heart, Lung, and Blood Institute, the Identification of Common Genetic Variants for Atrial Fibrillation and PR interval, the Robert Wood Johnson Foundation, and the American Heart Association and receiving an honorarium from the Coronary Artery Risk Development in Young Adults observational study monitoring board outside the submitted work. Dr De Filippis reported receiving grants from the National Institutes of Health during the conduct of the study and having a patent relating to assays to detect atherothrombosis outside the submitted work. Dr Blaha reported receiving grants from the National Institutes of Health, the US Food and Drug Administration, the American Heart Association, Aetna, and Amgen, and receiving personal fees from Amgen, Sanofi, Regeneron, Bayer Pharmaceuticals, Novo Nordisk, and Novartis outside the submitted work. No other disclosures were reported.
                Funding/Support: This research was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health and the US Food and Drug Administration Center for Tobacco Products under awards P50HL120163 and U54HL120163.
                Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
                Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the Food and Drug Administration, or the American Heart Association.
                Article
                zoi190637
                10.1001/jamanetworkopen.2019.16800
                6902792
                31800073
                f7d4c712-a0a0-4a6d-b40b-db495450f0de
                Copyright 2019 Obisesan OH et al. JAMA Network Open.

                This is an open access article distributed under the terms of the CC-BY License.

                History
                : 22 July 2019
                : 4 October 2019
                Categories
                Research
                Original Investigation
                Online Only
                Public Health

                Comments

                Comment on this article